Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gunagratinib
- Development stage
- Phase 2
- Lead developer
- InnoCare Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Gunagratinib (ICP-192) is a highly selective, orally active small-molecule pan-FGFR (fibroblast growth factor receptor) inhibitor that irreversibly inhibits FGFR activity by covalent binding. It is designed to overcome resistance to first-generation reversible FGFR inhibitors and demonstrates potent anti-tumor activity in preclinical and clinical studies. Gunagratinib is being developed primarily for the treatment of advanced solid tumors with FGFR gene aberrations, including cholangiocarcinoma and urothelial carcinoma. The drug has shown safety, tolerability, and preliminary efficacy in phase I/II trials for patients with FGF/FGFR gene alterations[1][2][3][4][5][6].
- Other names
- gunagratinibIBR822IBR-822IBR 822ICP-192ICP192ICP 192
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on gunagratinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gunagratinib.